Cytosorbents Corporation CTSO
$5.75
$0.020.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 13.86% | 6.69% | -73.41% | -262.73% | 231.71% |
| Total Depreciation and Amortization | 0.00% | -2.34% | -3.99% | -8.86% | 8.64% |
| Total Amortization of Deferred Charges | -3.09% | 16.87% | 31.05% | -0.52% | 0.53% |
| Total Other Non-Cash Items | -22.54% | 69.99% | 63.45% | 113.75% | -144.88% |
| Change in Net Operating Assets | 26.93% | 207.73% | -58.72% | -158.02% | 419.44% |
| Cash from Operations | 49.83% | 75.92% | -87.23% | -70.78% | 56.46% |
| Capital Expenditure | -27.27% | 89.81% | -535.29% | 54.05% | -1,750.00% |
| Sale of Property, Plant, and Equipment | 126.92% | -65.79% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.70% | 76.45% | -459.72% | 175.79% | -111.11% |
| Cash from Investing | 115.22% | 84.19% | -629.09% | 141.67% | -180.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | 177.19% | -116.88% | 1,025.34% | -156.81% | 817.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 72.14% | -11.58% | 51.76% | -92.77% | -141.36% |